Q1 Earnings Forecast for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – HC Wainwright issued their Q1 2027 EPS estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.91) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q2 2027 earnings at ($1.05) EPS, Q3 2027 earnings at ($1.19) EPS and Q4 2027 earnings at ($1.15) EPS.

MNPR has been the subject of a number of other reports. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Cantor Fitzgerald upgraded Monopar Therapeutics from a “neutral” rating to an “overweight” rating and set a $119.00 target price for the company in a research report on Thursday. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Finally, BTIG Research reiterated a “buy” rating on shares of Monopar Therapeutics in a research report on Thursday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics has an average rating of “Moderate Buy” and an average price target of $122.75.

Get Our Latest Report on MNPR

Monopar Therapeutics Price Performance

NASDAQ MNPR traded down $0.68 during trading hours on Friday, reaching $72.00. 203,206 shares of the stock traded hands, compared to its average volume of 145,014. The stock has a 50 day simple moving average of $82.59 and a two-hundred day simple moving average of $77.41. Monopar Therapeutics has a 1 year low of $50.07 and a 1 year high of $124.82. The company has a market cap of $483.12 million, a price-to-earnings ratio of -29.88 and a beta of 1.62.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.72).

Institutional Trading of Monopar Therapeutics

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new position in Monopar Therapeutics during the 2nd quarter valued at approximately $7,124,000. Siren L.L.C. lifted its holdings in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares during the period. Bank of America Corp DE grew its position in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC grew its position in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Monopar Therapeutics in the 1st quarter worth approximately $3,458,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Insider Buying and Selling

In other news, Director Kim Tsuchimoto sold 4,090 shares of Monopar Therapeutics stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total value of $455,585.10. Following the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Starr sold 8,400 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the completion of the sale, the director directly owned 5,173 shares of the company’s stock, valued at approximately $406,080.50. This trade represents a 61.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 51,920 shares of company stock worth $4,527,913 in the last ninety days. Corporate insiders own 9.70% of the company’s stock.

More Monopar Therapeutics News

Here’s some of the latest news about MNPR:

  • Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, implying substantial upside from the cited $72 share price. Cantor Fitzgerald rating article
  • Positive Sentiment: Monopar reported third-quarter 2026 EPS of a $0.72 loss, better than analysts’ consensus estimate of a $0.82 loss. The company also released quarterly results and business updates. Third-quarter results and business updates
  • Neutral Sentiment: HC Wainwright maintained its “Buy” rating and issued 2027 quarterly EPS estimates ranging from a $0.91 to a $1.19 loss per share. The projections indicate continued expected losses, but no change in rating was reported.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

Featured Articles

Earnings History and Estimates for Monopar Therapeutics (NASDAQ:MNPR)

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.